Correspondence 0001493152-23-013295 from ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: April 21, 2023 · CIK: 0001859007 · Accession: 0001493152-23-013295
AI Filing Summary & Sentiment
Letter
A.G.P./ALLIANCE GLOBAL PARTNERS
Madison Avenue 28th Floor New York,
New York 10022
April 21, 2023
VIA EDGAR
Securities and Exchange Commission 100 F Street, N.E.
Division of Corporation Finance
Washington, D.C. 20549
Re: ZyVersa Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333- 269442 (the “Registration Statement”)
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, (the “Act”), A.G.P./Alliance Global Partners, as the lead placement agent, hereby joins the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 9:00 a.m., Eastern Time on April 25, 2023, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that the placement agents have distributed as many copies of the Preliminary Prospectus to dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The undersigned, as the lead placement agent, represents that the co-placement agent has and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Please contact Katherine J. Blair of Manatt, Phelps & Phillips, LLP, counsel of the lead placement agent, at (310) 312-4252 to provide notice of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.
[Signature page follows]
Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS
Show Raw Text
CORRESP
1
filename1.htm
A.G.P./ALLIANCE
GLOBAL PARTNERS
590
Madison Avenue 28th Floor New York,
New
York 10022
April
21, 2023
VIA
EDGAR
Securities
and Exchange Commission 100 F Street, N.E.
Division
of Corporation Finance
Washington,
D.C. 20549
Re:
ZyVersa Therapeutics, Inc. (the “Company”)
Registration
Statement on Form S-1
File
No. 333- 269442 (the “Registration Statement”)
Ladies
and Gentlemen:
In
accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, (the “Act”),
A.G.P./Alliance Global Partners, as the lead placement agent, hereby joins the Company’s request for acceleration of the above-referenced
Registration Statement, requesting effectiveness for 9:00 a.m., Eastern Time on April 25, 2023, or as soon thereafter
as practicable.
Pursuant
to Rule 460 under the Act, we wish to advise you that the placement agents have distributed as many copies of the Preliminary Prospectus
to dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The
undersigned, as the lead placement agent, represents that the co-placement agent has and will comply with the requirements of Rule 15c2-8
under the Securities Exchange Act of 1934, as amended.
Please
contact Katherine J. Blair of Manatt, Phelps & Phillips, LLP, counsel of the lead placement agent, at (310) 312-4252 to provide notice
of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.
[Signature
page follows]
Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS
By:
/s/ Thomas Higgins
Name:
Thomas Higgins
Title:
Managing Director